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INTRODUCTION
Although the liver is the primary target for
hepatitis C virus (HCV) infection, it is well
established that many other organ systems are
affected, increasing the overall burden of dis-
ease [1–3]. In a recent article, Nun˜o Solinı´s and
co-authors assessed the overall disease burden
of chronic HCV across 354 clinical studies in
over 500,000 patients, including the impact of
early versus late treatment [4]. Their article
included some valuable insights into the con-
tributions that extrahepatic manifestations
(EHMs) make towards the overall morbidity and
mortality of the disease. The authors concluded
that early treatment leads to a strong and con-
sistent reduction in the burden of chronic
hepatitis C infection, from both clinical and
economic perspectives. The economic argu-
ment for early treatment has been addressed by
Nun˜o Solinı´s and colleagues [4]. in this
response, I highlight the burden of HCV EHMs
and present an ethical argument for treating
HCV early to minimize both the individual and
collective burdens of HCV-related diseases.
In the face of insurmountable evidence for
the benefit of treating patients early, a con-
certed effort is required to alter the actions of
governments and policymakers to realize real--
world changes in clinical practice. As the cur-
rent infected population ages, the burden of
decompensated cirrhosis and hepatocellular
carcinoma is set to rise until at least 2030, and
potentially beyond this in countries such as
Russia, where the number of new infections
continues to increase [5]. In a series of publica-
tions that modeled the future burden of HCV in
47 countries [5–7], the authors found rare
exceptions such as the Netherlands, where the
future burden of HCV is predicted to decrease
because the country has a high treatment rate
using newer therapies with high viral cure rates
[5].
Although the majority of governments pro-
vide limited access to newer and highly effective
direct-acting antivirals (DAAs), Nun˜o Solinı´s
and colleagues highlight examples of govern-
ment programs designed to widen access to
diagnosis and treatment of HCV infection [4].
These countries include Georgia, Mongolia,
Egypt, Australia, and France, and the outcomes
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of these programs should be closely monitored
to inform other countries’ health policy and
effect real-world changes to eliminate HCV
infection and reduce future HCV-related disease
burden.
HIGH COST OF EXTRAHEPATIC
DISEASE
EHMs such as neuropsychiatric conditions,
glomerulonephritis, and insulin resistance can
increase morbidity and mortality at all stages of
liver disease, not only when liver disease is
advanced [3]. The implications of extrahepatic
disease have far-reaching consequences, both
individual and societal. Studies have shown a
substantial negative effect of HCV on
health-related quality of life, including general
health and social functioning, which also
impacts work productivity [8, 9]. Viral eradica-
tion was associated with improved health-re-
lated quality of life and work productivity,
independent of liver fibrosis stage [9]. The eco-
nomic burden of HCV EHMs is considerable: a
recent meta-analysis reported that the esti-
mated direct costs were in the order of US$1.5
billion per year [10]. The cost is a reflection of
the diverse extrahepatic diseases associated with
HCV and the high proportion (up to 74%) of
patients with chronic HCV that are affected by
these diseases. The prevailing practice is to
delay treating patients with mild liver disease.
However, if patients are treated earlier, treat-
ment duration can potentially be shorter and
more effective, the progression towards cirrho-
sis and decompensated disease is reduced, and
the contribution of EHMs to all-cause morbidity
and mortality is diminished. Indeed, Nun˜o
Solinı´s et al. illustrate that a significant mortal-
ity benefit is gained in patients who achieve
SVR, at all stages of fibrosis [4]. The practice of
delaying HCV therapy also raises ethical issues
because it potentially allows the development
of avoidable extrahepatic diseases and denies an
improved quality of life after viral clearance
[10]. Evidence presented by Nun˜o Solinı´s and
colleagues show that delaying treatment could
substantially increase morbidity, mortality, and
medical costs [4]. The combined evidence from
this systematic review of the literature suggests
that early treatment intervention has a
demonstrable impact on morbidity and mor-
tality for patients with chronic HCV infection.
Reasons for delaying treatment are various,
but a significant motivation includes the
short-term economic cost of providing these
drugs. The evidence base presented shows that
treatment with DAAs is more cost-effective than
older, interferon-based regimens; it also shows
that treating patients with mild liver disease
(METAVIR; F1–2 fibrosis) is more cost-effective
than treating patients with more advanced liver
disease (F3–4 fibrosis). Taken together, these
two findings must call into question the value
of delaying treatment. Interestingly, this cor-
roborates the findings of a 2014 study by You-
nossi et al. [11] suggesting that the most
cost-effective strategy is to treat patients with-
out staging liver disease at all. Delaying treat-
ment also ignores the considerable cost of
treating and caring for patients with decom-
pensated liver disease and hepatocellular
carcinoma.
International HCV treatment guidelines
acknowledge a priority for treating patients
with EHMs owing to the clinical impact of
extrahepatic disease and the subsequent bene-
fits of treatment [12, 13].
This is a great step forward in reducing the
long-term morbidity and mortality of HCV, but
it is arguable that the best way to mitigate the
impact of extrahepatic diseases is to treat early,
before these complications are given a chance
to arise, an approach that the current evidence
base would suggest is both clinically validated
and cost-effective.
EHMS AND SCREENING
If the ultimate goal is to eradicate HCV, then a
greater effort is required to screen and treat
patients with HCV infection and prevent
ongoing transmission. In the US alone, up to
75% of people infected with HCV are unaware
of their infection [14]. The majority of patients
are diagnosed incidentally during evaluation of
liver transaminases or of at-risk populations
such as people who inject drugs [15].
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Furthermore, the majority of screening pro-
grams restrict coverage to known high-risk
groups, e.g. injection drug users and prisoners
[16]. An additional benefit—beyond reducing
long-term costs—for an increased recognition of
HCV EHMs could be an expansion of the pop-
ulation of patients screened for HCV. This is in
part supported by international guidelines stat-
ing that patients should be prioritized for
treatment if they have EHMs of HCV infection
[12]. An international group of experts [the
International Study Group of Extrahepatic
Manifestations Related to Hepatitis C Virus
(ISG-EHCV)] recently published an expert con-
sensus statement highlighting the need for a
multidisciplinary assessment of patients with
HCV infection to better diagnose EHMs [2].
Those EHMs with a strong or significant asso-
ciation with HCV based on epidemiological,
clinical, and laboratory evidence include mixed
cryoglobulinemia, diabetes, and cardiovascular
disease. A meta-analysis of 102 published stud-
ies found that diabetes and depression were
diagnosed in 15% and 25% of patients, respec-
tively [10]. These disorders could be included
alongside other high-risk groups or combined
with other negative predictors to improve HCV
screening [2].
COST-EFFECTIVENESS IN THE DAA
ERA
DAA regimens have been shown to be more
cost-effective partly owing to the superior effi-
cacy and safety profiles compared with those of
interferon-containing regimens. However, the
majority of the studies reviewed by Nun˜o Solinı´s
and colleagues were of interferon-containing
regimens and so there is still a need for a sys-
tematic review of the cost-effectiveness of DAAs.
Regardless of current strategies towards HCV
treatment, the cost to healthcare systems is set to
rise in the near future as we enter an era in which
patients who have long-standing HCV infection
will require greater access to care. This is evi-
denced by new data showing that HCV is an
independent risk factor for increased mortality
and resource utilization in the baby-boomer
cohort (adults born in 1945–1965) [17]. For this
well-defined group, who are five times more
likely to have chronic HCV [18], there is a strong
argument for widespread screening of baby
boomers and treating all those with chronic
HCV in order to substantially reduce the future
impact of hepatic and extrahepatic disease. In
the US, the Center for Disease Control has issued
recommendations that all baby boomers should
be given a one-time HCV test [18]. Although
there has been mixed success in delivering this
recommendation, with low uptake in pri-
mary-care settings, the use of electronic notifi-
cation systems in a variety of medical settings
has resulted in substantial increases in the
number of people screened [19, 20]. A recent
study in the US showed that investments in HCV
screening and treatment are expected to ‘‘break
even’’ from a social perspective after only
8–9 years when treatment is expanded to include
stages F0–F2, compared with 20–22 years when
treatment is limited to fibrosis stages F3–F4 [21].
SUMMARY
As demonstrated in the review by Nun˜o Solinı´s
et al. [4], we now have highly effective,
well-tolerated, and cost-effective therapies to
treat essentially anyone who is infected with
HCV. With these tools, we can prevent not only
hepatic but also many extrahepatic diseases
caused by HCV. As such, I believe that inter-
feron-free DAA therapy should be offered to
most patients that have HCV EHMs as well as to
all patients at risk of developing them. This
stands out as the best approach to deal with the
serious complications of chronic HCV infection
and to speed the way to a world in which HCV
is effectively eradicated.
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